World Journal of Urology

, Volume 32, Issue 3, pp 631–642 | Cite as

Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy

  • Dae Y. Kim
  • Jose A. Karam
  • Christopher G. WoodEmail author
Topic Paper


Numerous biological pathways are affected in renal cell carcinoma and the introduction of targeted agents has improved the survival of patients with advanced and metastatic disease. Durable and long-lasting cure is rarely achieved, and in select cases, the excision of metastatic deposits has shown to increase survival. Clinical trials of targeted agents are being explored as neoadjuvant and adjuvant therapies with the role of metastasectomy evolving in the treatment paradigm. This review examines published reports of metastasectomy and its developing role in the era of targeted therapy. A Medline search was conducted using keywords “metastasectomy,” “renal cell carcinoma,” and “targeted therapy,” and selected articles are discussed by examining prognostic stratification and metastasectomy in major anatomic regions. Most published reports span earlier periods of immunotherapy and chemotherapy, and henceforth, discussions are in historical context in this review. Although there is lack of Level 1 evidence, reports have suggested the prognostic value and survival benefit for metastasectomy in lesions that are amenable to complete resection after longer disease-free intervals in carefully selected patients with adequate performance status. Therefore, the role of metastasectomy must be further elucidated in the era of targeted therapy.


Kidney cancer Renal cell carcinoma Targeted therapy Metastasectomy 


Conflict of interest

Dae Y. Kim: None; Jose A. Karam: Pfizer Consultant; Christopher G. Wood: Pfizer Research Investigator, Argos Research Investigator, and GlaxoSmithKline Research Investigator.


  1. 1.
    Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR (2008) Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 113(1):78–83. doi: 10.1002/cncr.23518 PubMedCrossRefGoogle Scholar
  2. 2.
    Chen DY, Uzzo RG (2009) Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw: JNCCN 7(6):635–642 quiz 643PubMedCentralPubMedGoogle Scholar
  3. 3.
    Russo P (2011) The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am 25(4):737–752. doi: 10.1016/j.hoc.2011.04.009 PubMedCrossRefGoogle Scholar
  4. 4.
    Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 10(18 Pt 2):6335S–6341S. doi: 10.1158/1078-0432.CCR-sup-040026 CrossRefGoogle Scholar
  5. 5.
    Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970PubMedCrossRefGoogle Scholar
  6. 6.
    Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O’Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5):824–832PubMedCrossRefGoogle Scholar
  7. 7.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316(15):889–897. doi: 10.1056/nejm198704093161501 PubMedCrossRefGoogle Scholar
  8. 8.
    Vogelzang NJ, Lipton A, Figlin RA (1993) Subcutaneous interleukin-2 plus interferon α-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol: Off J Am Soc Clin Oncol 11(9):1809–1816Google Scholar
  9. 9.
    Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer: the Cochrane database of systematic reviews (1):CD001425. doi: 10.1002/14651858.CD001425.pub2
  10. 10.
    Kim B, Louie AC (1992) Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127(11):1343–1349 Chicago Ill: 1960PubMedCrossRefGoogle Scholar
  11. 11.
    Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51(6):933–937PubMedCrossRefGoogle Scholar
  12. 12.
    Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20(5):375–381. doi: 10.1097/MOU.0b013e32833c7ada PubMedCrossRefGoogle Scholar
  13. 13.
    Russo P, O’Brien MF (2008) Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 35(4):679–686. doi: 10.1016/j.ucl.2008.07.009 PubMedCrossRefGoogle Scholar
  14. 14.
    Staehler M (2011) The role of metastasectomy in metastatic renal cell carcinoma. Nat Rev Urol 8(4):180–181. doi: 10.1038/nrurol.2011.30 PubMedCrossRefGoogle Scholar
  15. 15.
    Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(1):16–24. doi: 10.1200/jco.2005.02.2574 CrossRefGoogle Scholar
  16. 16.
    Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(16):2505–2512. doi: 10.1200/jco.2005.03.6723 CrossRefGoogle Scholar
  17. 17.
    Rini BI, Sosman JA, Motzer RJ (2005) Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96(3):286–290. doi: 10.1111/j.1464-410X.2005.05616.x PubMedCrossRefGoogle Scholar
  18. 18.
    Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell cancer (RCC): a cochrane systematic review of published randomised trials. BJU Int 108(10):1556–1563. doi: 10.1111/j.1464-410X.2011.10629.x PubMedCrossRefGoogle Scholar
  19. 19.
    Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB (1997) Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158(5):1691–1695PubMedCrossRefGoogle Scholar
  20. 20.
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 17(8):2530–2540Google Scholar
  21. 21.
    Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 23(4):832–841. doi: 10.1200/JCO.2005.05.179 CrossRefGoogle Scholar
  22. 22.
    Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 20(1):289–296CrossRefGoogle Scholar
  23. 23.
    Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P (2008) Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 180(3):873–878. doi: 10.1016/j.juro.2008.05.006 discussion 878PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98(12):2566–2575. doi: 10.1002/cncr.11851 PubMedCrossRefGoogle Scholar
  25. 25.
    Lara PN, Jr., Tangen CM, Conlon SJ, Flanigan RC, Crawford ED, Southwest Oncology Group Trial S (2009) Predictors of survival of advanced renal cell carcinoma: long-term results from southwest oncology group trial S8949. J Urol 181(2):512–516. doi: 10.1016/j.juro.2008.10.021 discussion 516–517CrossRefGoogle Scholar
  26. 26.
    Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 16(6):2261–2266Google Scholar
  27. 27.
    Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48(1):77–81. doi: 10.1016/j.eururo.2005.03.004 discussion 81–72PubMedCrossRefGoogle Scholar
  28. 28.
    Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882. doi: 10.1002/cncr.25836 PubMedCrossRefGoogle Scholar
  29. 29.
    Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol: Off J Am Soc Clin Oncol 27(34):5794–5799. doi: 10.1200/JCO.2008.21.4809 CrossRefGoogle Scholar
  30. 30.
    Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Naito S, Tomita Y (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82(4):846–851. doi: 10.1016/j.urology.2013.06.035 PubMedCrossRefGoogle Scholar
  31. 31.
    Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I (2006) Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5(3):232–234. doi: 10.3816/CGC.2006.n.042 PubMedCrossRefGoogle Scholar
  32. 32.
    Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC (2009) Surgical resection of renal cell carcinoma after targeted therapy. J Urol 182(3):881–886. doi: 10.1016/j.juro.2009.05.014 PubMedCrossRefGoogle Scholar
  33. 33.
    Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439–444. doi: 10.1016/j.juro.2010.09.086 PubMedCrossRefGoogle Scholar
  34. 34.
    Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. doi: 10.1093/annonc/mdr362 PubMedCrossRefGoogle Scholar
  35. 35.
    Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, Svendsen E, Huang WL, Grundmann E, Eder M, Zwicknagl M et al (1988) Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol 114(6):605–612PubMedCrossRefGoogle Scholar
  36. 36.
    Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung. J Urol 42:269–276Google Scholar
  37. 37.
    Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI (1992) Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 54(1):33–38PubMedCrossRefGoogle Scholar
  38. 38.
    Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM, Blackstone EH (2005) Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 79(3):996–1003. doi: 10.1016/j.athoracsur.2004.08.034 PubMedCrossRefGoogle Scholar
  39. 39.
    Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, Pairolero PC (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57(2):339–344PubMedCrossRefGoogle Scholar
  40. 40.
    Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74(5):1653–1657PubMedCrossRefGoogle Scholar
  41. 41.
    Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M (2007) Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 84(4):1114–1120. doi: 10.1016/j.athoracsur.2007.04.118 PubMedCrossRefGoogle Scholar
  42. 42.
    Assouad J, Riquet M, Berna P, Danel C (2007) Intrapulmonary lymph node metastasis and renal cell carcinoma. Eur J Cardiothorac Surg 31(1):132–134. doi: 10.1016/j.ejcts.2006.10.025 PubMedCrossRefGoogle Scholar
  43. 43.
    Reinke RT, Higgins CB, Niwayama G, Harris RH, Friedman PJ (1976) Bilateral pulmonary hilar lymphadenopathy: an unusual manifestation of metastatic renal cell carcinoma. Radiology 121(1):49–53. doi: 10.1148/121.1.49 PubMedCrossRefGoogle Scholar
  44. 44.
    Winter H, Meimarakis G, Angele MK, Hummel M, Staehler M, Hoffmann RT, Hatz RA, Lohe F (2010) Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. J Urol 184(5):1888–1894. doi: 10.1016/j.juro.2010.06.096 PubMedCrossRefGoogle Scholar
  45. 45.
    Kawashima A, Nakayama M, Oka D, Sato M, Hatano K, Mukai M, Nagahara A, Nakai Y, Takayama H, Inoue M, Shiono H, Nishimura K, Okumura M, Nonomura N (2011) Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience. Int J Clin Oncol 16(6):660–665. doi: 10.1007/s10147-011-0244-0 PubMedCrossRefGoogle Scholar
  46. 46.
    Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Ruttinger D, Lohe F, Preissler G, Hatz RA, Winter H (2011) Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg 202(2):158–167. doi: 10.1016/j.amjsurg.2010.06.029 PubMedCrossRefGoogle Scholar
  47. 47.
    McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK (2013) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. doi: 10.1016/j.eururo.2013.08.012 PubMedGoogle Scholar
  48. 48.
    Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL (2010) Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(4):1185–1192. doi: 10.1016/j.ijrobp.2009.03.062 PubMedCrossRefGoogle Scholar
  49. 49.
    Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schoffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794–800. doi: 10.1093/annonc/mdq554 PubMedCrossRefGoogle Scholar
  50. 50.
    Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ (2008) Sorafenib for metastatic renal cancer: the princess Margaret experience. Am J Clin Oncol 31(2):182–187. doi: 10.1097/COC.0b013e3181574084 PubMedCrossRefGoogle Scholar
  51. 51.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi: 10.1002/cncr.25219 PubMedCrossRefGoogle Scholar
  52. 52.
    Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22(2):295–300. doi: 10.1093/annonc/mdq342 PubMedCrossRefGoogle Scholar
  53. 53.
    Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794–1801. doi: 10.2106/JBJS.F.00603 PubMedCrossRefGoogle Scholar
  54. 54.
    Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, Sylvester R, Group EGTC (2009) Radical nephrectomy with and without lymph-node dissection: final results of European organization for research and treatment of cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55(1):28–34. doi: 10.1016/j.eururo.2008.09.052 CrossRefGoogle Scholar
  55. 55.
    Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H (2011) Lymph node dissection in renal cell carcinoma. Eur Urol 60(6):1212–1220. doi: 10.1016/j.eururo.2011.09.003 PubMedCrossRefGoogle Scholar
  56. 56.
    Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML (2008) Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 180(1):99–103. doi: 10.1016/j.juro.2008.03.025 PubMedCrossRefGoogle Scholar
  57. 57.
    Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D (2006) Outcome following hepatic resection of metastatic renal tumors: the Paul brousse hospital experience. HPB 8(2):100–105. doi: 10.1080/13651820500496266 PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O, Wolfgang CL, Aldrighetti L, Crawford M, Choti MA, Pawlik TM (2012) A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB 14(8):532–538. doi: 10.1111/j.1477-2574.2012.00495.x PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Ruys AT, Tanis PJ, Iris ND, van Duijvendijk P, Verhoef C, Porte RJ, van Gulik TM (2011) Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 18(7):1932–1938. doi: 10.1245/s10434-010-1526-x PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98(2):342–349. doi: 10.3171/jns.2003.98.2.0342 PubMedCrossRefGoogle Scholar
  61. 61.
    Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS (2008) Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 113(7):1641–1648. doi: 10.1002/cncr.23769 PubMedCrossRefGoogle Scholar
  62. 62.
    Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53(2):376–381. doi: 10.1016/j.eururo.2007.08.053 PubMedCrossRefGoogle Scholar
  63. 63.
    Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP (2007) Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 27(6C):4255–4257PubMedGoogle Scholar
  64. 64.
    Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958–4965. doi: 10.1002/cncr.26138 PubMedCrossRefGoogle Scholar
  65. 65.
    Soffietti R, Trevisan E, Ruda R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6):679–686. doi: 10.1097/CCO.0b013e3283571a1c PubMedCrossRefGoogle Scholar
  66. 66.
    Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL (2012) The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116(5):978–983. doi: 10.3171/2012.2.JNS111353 PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ (2009) Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96(6):579–592. doi: 10.1002/bjs.6606 PubMedCrossRefGoogle Scholar
  68. 68.
    Chung AY, Tran TB, Brumund KT, Weisman RA, Bouvet M (2012) Metastases to the thyroid: a review of the literature from the last decade. Thyroid 22(3):258–268. doi: 10.1089/thy.2010.0154 PubMedCrossRefGoogle Scholar
  69. 69.
    Hegerova L, Griebeler ML, Reynolds JP, Henry MR, Gharib H (2013) Metastasis to the thyroid gland: report of a large series from the mayo clinic. Am J Clin Oncol. doi: 10.1097/COC.0b013e31829d1d09 PubMedGoogle Scholar
  70. 70.
    Antonelli A, Arrighi N, Corti S, Legramanti S, Zanotelli T, Cozzoli A, Cunico SC, Simeone C (2012) Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). BJU Int 110(11 Pt B):E559–E563. doi: 10.1111/j.1464-410X.2012.11271.x PubMedCrossRefGoogle Scholar
  71. 71.
    Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, Group EGW (2011) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):Vi25–vi30. doi: 10.1093/annonc/mdr372 PubMedGoogle Scholar
  72. 72.
    Ismaili N (2011) Treatment of colorectal liver metastases. World J Surg Oncol 9:154. doi: 10.1186/1477-7819-9-154 PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E (2009) Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456–460. doi: 10.1111/j.1464-410X.2009.08490.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Dae Y. Kim
    • 1
  • Jose A. Karam
    • 1
  • Christopher G. Wood
    • 1
    Email author
  1. 1.MD Anderson Cancer CenterHoustonUSA

Personalised recommendations